[CAS NO. 1550008-55-3] ML264

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1550008-55-3]

Catalog

SLK-S8196

Brand

Selleck

CAS

1550008-55-3

DESCRIPTION [1550008-55-3]

Overview

MDL	MFCD30187519
Molecular Weight	384.88
Molecular Formula	C17H21ClN2O4S
SMILES	O=C(NCC(N(C)C(CC1)CCS1(=O)=O)=O)/C=C/C2=CC=CC(Cl)=C2

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.5982 mL	12.9911 mL	25.9821 mL
5 mM	0.5196 mL	2.5982 mL	5.1964 mL
10 mM	0.2598 mL	1.2991 mL	2.5982 mL
50 mM	0.0520 mL	0.2598 mL	0.5196 mL

Description

ML264 (CID-51003603), a selectively inhibitor of ,potently Inhibits Growth of Colorectal Cancer.

Targets

KLF5 ^[1]
(Cell-based assay for proliferation of DLD-1 cells)

29 nM

In vitro

ML264 potently halts DLD-1 viability (IC50 = 29 nM) with high maximal effect (>90%). DLD-1 cells are human colorectal adenocarcinoma cells. ML264 has significant effects at submicromolar doses on other cell types as well, including HCT116 (human colorectal carcinoma), HT29 (human colorectal adenocarcinoma), and SW620 (human colorectal adenocarcinoma). The IEC-6 anti-target (a nontransformed rat intestinal epithelial cell line) is largely unaffected, with inhibition below 50% at the highest dose.This compound potently inhibits proliferation of CRC cells in vitro through modifications of the cell cycle profile.

In vivo

In an established xenograft mouse model of colon cancer, ML264 efficiently inhibits growth of the tumor within five days of treatment. this effect is caused by a significant reduction in proliferation and that ML264 potently inhibits the expression of KLF5 and EGR1, a transcriptional activator of KLF5.

References

[1] Bialkowska A,et al. Probe Reports from the NIH Molecular Libraries Program. 2010-2011 Oct 31 [updated 2013 Mar 7].
[2] Ruiz de Sabando A, et al. Mol Cancer Ther. 2016, 15(1):72-83.